Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Coagulation Factor Deficiency Market from 2024 to 2025?
The market for deficiency in coagulation factors has been experiencing robust growth over the last few years. It is projected to expand from $4.58 billion in 2024 to $4.94 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. Factors that drove this expansion in the past include the increasing visibility of hemophilia, the development of recombinant factors, heightened awareness regarding coagulation disorders, improved diagnostic capabilities, governmental support for rare disease treatment, the advent of prophylactic treatments, the broadening of patient registries, and escalated investments into biotechnology.
What Is the Projected Market Size of the Coagulation Factor Deficiency Market?
The market for coagulation factor deficiency is predicted to witness robust expansion in the forthcoming years. The market size is projected to reach $6.64 billion by 2029, with a compound annual growth rate (CAGR) of 7.7%. The hike in the projected period is due to the increasing trend of gene therapies, enhanced focus on personalized medicine, escalating cases of coagulation disorders, increased penetration in newly emerging markets, and the convergence of digital health solutions and ongoing innovation in biomanufacturing technologies. Noteworthy trends during the forecast period encompass gene editing technologies like CRISPR, creation of long-lasting recombinant factors, progress in gene therapy delivery systems, wearable devices for coagulation monitoring, utilization of artificial intelligence for optimizing treatment, point-of-care diagnostic instruments, drug delivery via nanoparticles, development of recombinant products without plasma, innovation in biosimilars, and the harmony of precision medicine methodologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21152&type=smp
Who are the Major Competitors in the Coagulation Factor Deficiency Market Outlook?
Major companies operating in the coagulation factor deficiency market are Pfizer Inc., F Hoffmann-La Roche Ltd., Bayer HealthCare Pharmaceuticals, Sanofi Genzyme, Novo Nordisk A/S, Baxter International Inc., CSL Behring LLC, Grifols S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, Swedish Orphan Biovitrum AB, GC Biopharma Co. Ltd., Alnylam Pharmaceuticals Inc., Opko Health Inc., Kedrion Biopharma Inc., Shanghai RAAS Blood Products Co. Ltd., LFB S.A., Biotest AG, Spark Therapeutics Inc., Biogen Inc., Sangamo Therapeutics Inc., Centessa Pharmaceuticals Inc.
What Is Fueling Growth in the Coagulation Factor Deficiency Market?
The rise in blood-related disorders is anticipated to spur the growth of the coagulation factor deficiency market. These disorders are a collection of conditions impacting the production, functionality, or makeup of blood cells, plasma, or platelets. They can result in complications such as anemia, clotting issues, or immune system deficiencies. The surge in these disorders can be attributed to factors like aging populations, genetic predispositions, heightened awareness, environmental factors, lifestyle alterations, the increasing load of chronic illnesses, and innovations in diagnostic technologies enabling early detection. Coagulation factor deficiency plays a significant role in managing these disorders as it provides vital clotting factors necessary to prevent or manage excessive bleeding, particularly in conditions like hemophilia where the natural clotting ability is diminished. In September 2024, the Leukemia and Lymphoma Society, reported that every three minutes, one person in the U.S. is diagnosed with leukemia, lymphoma, or myeloma. In the same year, an estimated 187,740 individuals were diagnosed with such cancers, which made up 9.4% of the anticipated 2,001,140 new cancer cases in the U.S. Furthermore, in May 2024, as per the National Health Service (NHS) England, around 17,000 individuals in England are living with sickle cell disease, a genetically inherited blood disorder, with approximately 250 new cases appearing annually. Consequently, the mounting incidence of blood-related disorders is fueling the growth of the coagulation factor deficiency market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21152&type=smp
Which Coagulation Factor Deficiency Market Segments Are Growing the Fastest?
The coagulation factor deficiency market covered in this report is segmented –
1) By Product: Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates, Biologics, Desmopressin, Other Product Types
2) By Deficiency Type: Haemophilia A, Hemophilia B, Von Willebrand Disease, Factor XI Deficiency, Factor XIII Deficiency, Other Treatment Types
3) By End Users: Hospitals, Clinics, Home Care, Other End Users
Subsegments:
1) By Recombinant Coagulation Factor Concentrates: Recombinant Factor VIII, Recombinant Factor IX, Recombinant Factor VIIa, Other Recombinant Factors
2) By Plasma-derived Coagulation Factor Concentrates: Plasma-derived Factor VIII, Plasma-derived Factor IX, Plasma-derived Factor VII, Other Plasma-derived Factors
3) By Biologics: Monoclonal Antibodies, Gene Therapy Products
4) By Desmopressin: Intravenous Desmopressin, Intranasal Desmopressin
5) By Other Product Types: Fresh Frozen Plasma (FFP), Prothrombin Complex Concentrates (PCC)
Which Industry Trends Are Shaping the Future of the Coagulation Factor Deficiency Market?
Leading entities in the coagulation factor deficiency market are channeling their efforts into crafting revolutionary treatments such as one-time gene therapy, which offers enduring, if not permanent, solutions for individuals suffering from bleeding complications such as hemophilia, thus decreasing the necessity for persistent infusions of clotting factors. One-time gene therapy is a medical intervention that entails the modification or infusion of genetic information inside a patient’s cells for the purpose of treating or potentially eradicating a disease, aiming to provide durable or permanent benefits after a singular administration. For example, in April 2024, Pfizer Inc., a pharmaceutical and biotechnology firm based in the USA, declared that BEQVEZ (fidanacogene elaparvovec-dzkt) received approval from the U.S. Food and Drug Administration (FDA) intended for the treatment of adults suffering from moderate to severe Hemophilia B currently on factor IX (FIX) prophylaxis therapy. This one-time adeno-associated virus (AAV)-based gene therapy is designed to implant a functional version of the FIX gene encoding a high-activity FIX variant in the transduced cells. This gene therapy allows Hemophilia B patients to generate FIX on their own through this one-time treatment as opposed to requiring regular infusions of FIX.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/coagulation-factor-deficiency-global-market-report
Which Countries Are Leading the Coagulation Factor Deficiency Market?
North America was the largest region in the coagulation factor deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagulation factor deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21152
This Report Delivers Insight On:
1. How big is the coagulation factor deficiency market, and how is it changing globally?
2. Who are the major companies in the coagulation factor deficiency market, and how are they performing?
3. What are the key opportunities and risks in the coagulation factor deficiency market right now?
4. Which products or customer segments are growing the most in the coagulation factor deficiency market?
5. What factors are helping or slowing down the growth of the coagulation factor deficiency market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model